Serotonin synthesis rate and the tryptophan hydroxylase-2: G-703T polymorphism in social anxiety disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
It is disputed whether anxiety disorders, like social anxiety disorder, are characterized by serotonin over- or underactivity. Here, we evaluated whether our recent finding of elevated neural serotonin synthesis rate in patients with social anxiety disorder could be reproduced in a separate cohort, and whether allelic variation in the tryptophan hydroxylase-2 (TPH2) G-703T polymorphism relates to differences in serotonin synthesis assessed with positron emission tomography. Eighteen social anxiety disorder patients and six healthy controls were scanned during 60 minutes in a resting state using positron emission tomography and 5-hydroxy-L-[β -11 C]tryptophan, [11 C]5-HTP, a substrate of the second enzymatic step in serotonin synthesis. Parametric images were generated, using the reference Patlak method, and analysed using Statistical Parametric Mapping (SPM8). Blood samples for genotyping of the TPH2 G-703T polymorphism were obtained from 16 social anxiety disorder patients (T carriers: n=5, GG carriers: n=11). A significantly elevated [11 C]5-HTP accumulation rate, indicative of enhanced decarboxylase activity and thereby serotonin synthesis capacity, was detected in social anxiety disorder patients compared with controls in the hippocampus and basal ganglia nuclei and, at a more lenient (uncorrected) statistical threshold, in the amygdala and anterior cingulate cortex. In patients, the serotonin synthesis rate in the amygdala and anterior cingulate cortex was significantly elevated in TPH2 T carriers in comparison with GG homozygotes. Our results support that social anxiety disorder entails an overactive presynaptic serotonergic system that, in turn, seems functionally influenced by the TPH2 G-703T polymorphism in emotionally relevant brain regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100 · cited 1×
“Serotonin (5-hydroxytryptamine (5-HT)) is a central monoamine neurotransmitter involved in many behavioural functions including regulation of mood and anxiety (Berger et al., 2009; Hale et al., 2012).”
BackgroundThe Neurocircuitry of Fear, Stress, and Anxiety Disorders
Shin, L. M., & Liberzon, I. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.83 · Cited by 2,083 · cited 1×
“It should also be noted that we found an effect in the opposite direction, that is, higher synthesis rate in GG relative to T carriers, in the right dorsolateral prefrontal cortex, suggested to be involved in top-down regulation of amygdala activity (Shin and Liberzon, 2010).”
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680 · cited 1×
“Pharmaceuticals targeting the serotonin system are widely used for the treatment of anxiety, in particular selective serotonin reuptake inhibitors (SSRIs) are effective in SAD (Blanco et al., 2013; Mayo-Wilson et al., 2014).”
MethodBrühl, A. B., Delsignore, A., Komossa, K., & Weidt, S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.003 · Cited by 439
A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity
Brown, S. M., Peet, E., Manuck, S. B., Williamson, D. E., Dahl, R. E., Ferrell, R. E., & Hariri, A. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001716 · Cited by 241
Furmark, T., Appel, L., Henningsson, S., Åhs, F., Faria, V., Linnman, C., Pissiota, A., Frans, Ö., Bani, M., Bettica, P., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2534-08.2008 · Cited by 210 · cited 6×
“…show enhanced amygdala responsiveness to negative facial stimuli (Furmark et al., 2009), and patients with the T genotype also show compromised attenuation of amygdala activity and poorer clinical response to pill placebo when treated under double-blind randomized conditions (Furmark et al., 2008).”
BackgroundMethodInfluentialSelf-citationAmygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation
Canli, T., Congdon, E., Gutknecht, L., Constable, R. T., & Lesch, K. P. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0391-4 · Cited by 188 · cited 3×
“…et al., 2010), altered anxiety-related amygdala-hippocampal interconnectivity (Hahn et al., 2013) and increased amygdala reactivity to negative emotional stimuli both in healthy volunteers (Brown et al., 2005; Canli et al., 2005; Hermann et al., 2012) and in SAD patients (Furmark et al., 2009).”
BackgroundCapacity for 5-HT1A–mediated autoregulation predicts amygdala reactivity
Fisher, P. M., Meltzer, C. C., Ziolko, S. K., Price, J. C., Moses-Kolko, E. L., Berga, S. L., & Hariri, A. R. (2006) · Nature Neuroscience · doi:10.1038/nn1780 · Cited by 156 · cited 2×
“imaging studies indicate a positive relationship between extracellular serotonin and emotionally induced reactivity in the amygdala (Rhodes et al., 2007; Fisher et al., 2006).”
BackgroundResultThe evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99 · cited 1×
“Pharmaceuticals targeting the serotonin system are widely used for the treatment of anxiety, in particular selective serotonin reuptake inhibitors (SSRIs) are effective in SAD (Blanco et al., 2013; Mayo-Wilson et al., 2014).”
MethodHuman 5-HT Transporter Availability Predicts Amygdala Reactivity In Vivo
Rhodes, R. A., Murthy, N. V., Dresner, M. A., Selvaraj, S., Stavrakakis, N., Babar, S., Cowen, P. J., & Grasby, P. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1175-07.2007 · Cited by 93 · cited 2×
“imaging studies indicate a positive relationship between extracellular serotonin and emotionally induced reactivity in the amygdala (Rhodes et al., 2007; Fisher et al., 2006).”
BackgroundResultAndersson, E., Rück, C., Lavebratt, C., Hedman, E., Schalling, M., Lindefors, N., Eriksson, E., Carlbring, P., Andersson, G., & Furmark, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079015 · Cited by 43 · cited 3×
“The TPH2 G-703T SNP has also been reported to influence the short-term but not the long-term response to cognitive-behavioural treatment of SAD (Andersson et al., 2013).”
BackgroundInfluentialSelf-citationTPH2 gene variation and conflict processing in a cognitive and an emotional Stroop task
Osinsky, R., Schmitz, A., Alexander, N., Kuepper, Y., Kozyra, E., & Hennig, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.022 · Cited by 34 · cited 3×
“Differences in promoter activity between the TPH2 T and GG variants have been assumed (Hermann et al., 2012, Osinsky et al., 2009) implying that there are genotype-dependent differences in serotonin levels with TPH2 T carriers belonging to a high serotonin-level group (Hahn et al., 2013).”
Background
Cited by
Genetic risk variants for social anxiety
Stein, M. B., Chen, C., Jain, S., Jensen, K. P., He, F., Heeringa, S. G., Kessler, R. C., Maihofer, A., Nock, M. K., Ripke, S., et al. (2017) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32520 · Cited by 72
Frick, A., Åhs, F., Appel, L., Jonasson, M., Wahlstedt, K., Bani, M., Merlo Pich, E., Bettica, P., Långström, B., Lubberink, M., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.09.004 · Cited by 22
Self-citationPersonalized Clinical Approaches to Anxiety Disorders
Perna, G., Alciati, A., Sangiorgio, E., Caldirola, D., & Nemeroff, C. B. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_25 · Cited by 15
The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11
Maron, E., Lan, C.-C., & Nutt, D. (2018) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2018_49 · Cited by 9
Metadata
- Authors
- Furmark, T., Marteinsdottir, I., Frick, A., Heurling, K., Tillfors, M., Appel, L., Antoni, G., Hartvig, P., Fischer, H., Långström, B., Eriksson, E., & Fredrikson, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-07-10
- Volume
- 30
- Issue
- 10
- Pages
- 1028-1035
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2403002833
- Cited by
- 37
- References
- 13
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.